All In MedTech

FDA Clearance Tracker · P000036

DERMAGRAFT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 28, 2001 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 28, 2001

Approved (conversion)

Time to decision

399 days

Received Aug 25, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P000036
Device name
DERMAGRAFT
Applicant location
San Diego, CA
Received
Aug 25, 2000
Decided
Sep 28, 2001
Decision
Approved (conversion)
Supplements
14 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MGR

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE DERMAGRAFT(R). THE DEVICE IS INDICATED FOR USE IN THE TREATMENT OF FULL-THICKNESS DIABETIC FOOT ULCERS GREATER THAN SIX WEEKS DURATION WHICH EXTEND THROUGH THE DERMIS, BUT WITHOUT TENDON MUSCLE, JOINT CAPSULE OR BONE EXPOSURE. DERMAGRAFT(R) SHOULD BE USED IN CONJUNCTION WITH STANDARD WOUND CARE REGIMENS AND IN PATIENTS THAT HAVE ADEQUATE BLOOD SUPPLY TO THE INVOLVED FOOT.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MGR. The earliest in FDA's data is P900033, decided Mar 1, 1996.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Shire Regenerative Medicine

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.